Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

NCT05722171 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

BIOLOGICAL: gdT cell injection targeting B7-H3 chimeric antigen receptor

Sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.